Maternal And Infant Outcomes Of Patients With Pregnancy-associated Breast Cancer After Chemotherapy During Pregnancy:A Meta-analysis Of Single Rate

Objective: This single rate meta-analysis summarized the literature on maternal and infant outcomes after chemotherapy in pregnancy-associated breast cancer(PABC)patients and sought to provide reference for chemotherapy during pregnancy.Methods: Pub Med,Cochrane Library and Embase databases were searched from January 1980 to December 2019,to include relevant studies in this single rate meta-analysis.Literature screening and data extraction were carried out according to inclusion and exclusion criteria.Stata/SE 11.0 was used for this analysis.The incidence of premature delivery,maternal and neonatal complications,stillbirth,and neonatal congenital malformation were calculated.Results: A total of 12 studies were included in this meta-analysis.The incidence of pregnancy outcomes in patients with pregnancy-associated breast cancer after chemotherapy during pregnancy was calculated.The incidence of the premature delivery is 31.13%(95%CI: 22.96%-37.77%).The incidence of maternal complications is 19.42%(95%CI: 13.49%-24.64%).The incidence of neonatal complications is 14.75%(95%CI: 10.31%-18.77%).The incidence of stillbirth is 0.60%.The incidence of neonatal congenital malformation is 3.85%(95%CI: 2.25%-5.39%).Conclusions:1.In this Meta-analysis,the incidence of preterm birth in PABC patients receiving chemotherapy during pregnancy is higher than that in the general population.The incidence of stillbirth and neonatal congenital malformations is not higher than the general population.The incidence of total maternal complications is 19.42%,and the incidence of common complications is not higher than the general population.The incidence of total neonatal complications is 14.75%,and the incidence of common complications is not higher than the general population.2.It is safe for patients with PABC to receive chemotherapy(anthracyclines based)during the second and trimesters of pregnancy.However,studies with larger sample size and longer follow-up of children are required to evaluate possible late side effects.